Literature DB >> 15871017

Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma.

Kazutaka Takagi, Akira Yoshida, Hiromichi Iwasaki, Hitoshi Inoue, Takanori Ueda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15871017     DOI： 10.1007/s00277-005-1050-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

1.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

2.  Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis.

Authors:  William S Baek; Asad Bashey; Geoffrey L Sheean
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-07       Impact factor: 10.154

Review 3.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

Review 4.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.